Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Advances in HBV DNA assays are key to determine best long-term treatment strategies for Hepatitis B

10.01.2005


For the 350 million people chronically infected with HBV, the two therapeutic approaches currently available are immunomodulatory agents and antiviral chemotherapy. The first therapeutic agent was interferon-alpha (IFN-alpha), whose dual mode of action includes both antiviral and immunomodulatory effects. Unfortunately, extended IFN-alpha treatment is effective in no more than 15-25% of patients, and is associated with a wide spectrum of adverse reactions, although these limitations will be partially obviated by the likely approval of peginterferon-alpha for use in chronic HBV in the near future.



It is the nucleoside analogue named lamivudine that has become the gold standard worldwide for use in patients with chronic hepatitis B. Nevertheless, lamivudine-induced decreases in viral load are difficult to sustain over time due to occurrence of viral drug resistance. The drug resistance is associated with mutations in the very conserved catalytic polymerase /reverse transcriptase domain of the gene located at the YMDD motif.

The recent arrival of nucleotide analogue of HBV therapy is adefovir dipivoxil, whose antiviral efficacy was confirmed in large-scale clinical trials in both HBeAg-positive and HBeAg-negative chronic hepatitis B patients, achieving more than a 3-log decrease in viral load, drop in serum ALT levels, and improvement in liver histology after one to two years of treatment. Although virus resistant mutants did not seem to occur in adefovir-treated patients in 48 weeks and then up to 60 weeks of treatment, this did not turn out to be the case upon treatment after 96 weeks. The newly discovered mutant to adefovir (rtN236T) is located downstream from the YMDD motif in the D domain of the viral polymerase.


Clinically relevant prediction and monitoring of viral resistance require the use of existing tools such as drug resistance and viral load testing. It might also have to extend to include the detection of mutations in the precore and core promoter regions as well as HBV genotyping.

Advances in molecular diagnosis of drug resistance using highly sensitive methodologies such as DNA hybridization assays can pinpoint the type of mutation responsible and, more importantly, detect upcoming viral resistance at an early stage when the variant represents only a minor fraction of the total viral population. Such new tools are especially relevant for patients at high risk for disease progression or acute exacerbation.

The diagnostic developments play important roles in HBV patient management, and in determining the best long-term treatment strategies (sequential, combined, etc.) for the use of the new drugs. At the same time, it is desirable to integrate the HBV diagnostic testing with new therapeutic agents in order to ensure optimized, tailored patient treatment.

Anita Bay | alfa
Further information:
http://www.medsci.org
http://www.medsci.org/v02p0008.htm

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>